Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism (Q28208349)

2

0 references

M Ito

3

0 references

T Saeki

4

0 references

I Yoshida

5

0 references

T Okada

6

0 references

H Ikuta

7

0 references

D Shinmyo

8

0 references

K Tanaka

9

0 references

N Kurusu

10

0 references

H Tanaka

European Journal of Pharmacology

11

0 references

language of work or name

English

0 references

publication date

23 November 2001

0 references

published in

0 references

volume

431

0 references

issue

3

0 references

page(s)

345-52

0 references

cites work

Hypertriglyceridemia as a cardiovascular risk factor

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Lowering effects of four different statins on serum triglyceride level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Concentration and composition of lipoproteins in blood plasma of the WHHL rabbit. An animal model of human familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Squalene synthase inhibition alters metabolism of nonsterols in rat liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Pravastatin decreases serum lipids and vascular cholesterol deposition in Watanabe heritable hyperlipidemic (WHHL) rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Isolation and use of liver cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Triglyceride metabolism in heterozygote of Watanabe heritable hyperlipidemic rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Triglycerides as a risk factor for coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Comparison of statins in hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

WHHL-rabbit: a low density lipoprotein receptor-deficient animal model for familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9

Hypolipidemic effects of CS-500 (ML-236B) in WHHL-rabbit, a heritable animal model for hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901450-9